AstraZeneca

STUDY REPORT SUMMARY

ASTRAZENECA MC Latvia

FINISHED PRODUCT: Seroquel XR 300mg; 400mg
ACTIVE INGREDIENT: quetiapine

Study No: NIS-NLV-SER-2008/1
Observation of change in Clinical Global Impression scores in Schizophrenia Patients receiving Seroquel XR Treatment

Developmental phase: Non-interventional study
Study Completion Date: 31 January 2009
Date of Report: 20 March 2009

OBJECTIVES:

Primary objective is to assess severity of illness in schizophrenia patients at the time of entry in the study and after the treatment with Seroquel XR by using CGI (Clinical Global Impression) scores
Evaluate schizophrenia symptoms using BPRS (Brief Psychiatric Rating Scale).

METHODS:

The analyses consisted of descriptive statistics and plots, illustrating different aspects of the daily use of Seroquel XR.

RESULTS:

40 specialists evaluated 80 schizophrenia patients during 3 visits at 4 weeks intervals. Patient compliance >80% at visit 2 was 76%, at visit 3 – 83%. Patients evaluated improvement in their condition as follows: 29,7% - very good; 43,2% - rather good; 25,7 – slight improvement; 1,35% - no improvement. Therapy effectiveness evaluated by physician: 7% - important improvement/almost full recovery; 67% - partial improvement/ partial recovery; 25% - minimal improvement/ stable disease; 1% - no improvement or worsening. The results suggest that the Seroquel XR therapy is effective, easy to dose once daily and with good tolerability and compliance.